JP5122950B2 - （３ｒ）−１−（２−メチルアラニル−ｄ−トリプトフィル）−３−（フェニルメチル）−３−ピペリジンカルボン酸１，２，２−トリメチルヒドラジドの結晶形 - Google Patents

（３ｒ）−１−（２−メチルアラニル−ｄ−トリプトフィル）−３−（フェニルメチル）−３−ピペリジンカルボン酸１，２，２−トリメチルヒドラジドの結晶形 Download PDF

Info

Publication number
JP5122950B2
JP5122950B2 JP2007519301A JP2007519301A JP5122950B2 JP 5122950 B2 JP5122950 B2 JP 5122950B2 JP 2007519301 A JP2007519301 A JP 2007519301A JP 2007519301 A JP2007519301 A JP 2007519301A JP 5122950 B2 JP5122950 B2 JP 5122950B2
Authority
JP
Japan
Prior art keywords
methylalanyl
phenylmethyl
trimethylhydrazide
tryptophyll
piperidinecarboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2007519301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008505078A (ja
JP2008505078A5 (enExample
Inventor
ロリマー キース
エイチ．パインズ シーモン
Original Assignee
ヘルシン セラピューティクス（ユー．エス．），インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘルシン セラピューティクス（ユー．エス．），インコーポレイティド filed Critical ヘルシン セラピューティクス（ユー．エス．），インコーポレイティド
Publication of JP2008505078A publication Critical patent/JP2008505078A/ja
Publication of JP2008505078A5 publication Critical patent/JP2008505078A5/ja
Application granted granted Critical
Publication of JP5122950B2 publication Critical patent/JP5122950B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)
JP2007519301A 2004-06-29 2005-06-22 （３ｒ）−１−（２−メチルアラニル−ｄ−トリプトフィル）−３−（フェニルメチル）−３−ピペリジンカルボン酸１，２，２−トリメチルヒドラジドの結晶形 Expired - Lifetime JP5122950B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58375704P 2004-06-29 2004-06-29
US60/583,757 2004-06-29
PCT/US2005/022408 WO2006016995A1 (en) 2004-06-29 2005-06-22 Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012134975A Division JP5718286B2 (ja) 2004-06-29 2012-06-14 （３ｒ）−１−（２−メチルアラニル−ｄ−トリプトフィル）−３−（フェニルメチル）−３−ピペリジンカルボン酸１，２，２−トリメチルヒドラジドの結晶形

Publications (3)

Publication Number Publication Date
JP2008505078A JP2008505078A (ja) 2008-02-21
JP2008505078A5 JP2008505078A5 (enExample) 2008-07-17
JP5122950B2 true JP5122950B2 (ja) 2013-01-16

Family

ID=35064648

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007519301A Expired - Lifetime JP5122950B2 (ja) 2004-06-29 2005-06-22 （３ｒ）−１−（２−メチルアラニル−ｄ−トリプトフィル）−３−（フェニルメチル）−３−ピペリジンカルボン酸１，２，２−トリメチルヒドラジドの結晶形
JP2012134975A Expired - Lifetime JP5718286B2 (ja) 2004-06-29 2012-06-14 （３ｒ）−１−（２−メチルアラニル−ｄ−トリプトフィル）−３−（フェニルメチル）−３−ピペリジンカルボン酸１，２，２−トリメチルヒドラジドの結晶形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012134975A Expired - Lifetime JP5718286B2 (ja) 2004-06-29 2012-06-14 （３ｒ）−１−（２−メチルアラニル−ｄ−トリプトフィル）−３−（フェニルメチル）−３−ピペリジンカルボン酸１，２，２−トリメチルヒドラジドの結晶形

Country Status (9)

Country Link
US (2) US7825138B2 (enExample)
EP (2) EP1768976B1 (enExample)
JP (2) JP5122950B2 (enExample)
KR (1) KR101324340B1 (enExample)
CN (3) CN1976921B (enExample)
CA (1) CA2572325C (enExample)
IL (1) IL180336A0 (enExample)
MX (1) MXPA06015003A (enExample)
WO (1) WO2006016995A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012188452A (ja) * 2004-06-29 2012-10-04 Helsinn Therapeutics (Us) Inc （３ｒ）−１−（２−メチルアラニル−ｄ−トリプトフィル）−３−（フェニルメチル）−３−ピペリジンカルボン酸１，２，２−トリメチルヒドラジドの結晶形

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130281701A1 (en) 2004-06-29 2013-10-24 Helsinn Therapeutics (U.S.), Inc. Crystal forms of anamorelin
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
CA2900322C (en) * 2013-02-21 2019-03-26 Pfizer Inc. Solid forms of the selective cdk4/6 inhibitor compound acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8h-pyrido[2,3-d]pyrimidin-7-one
HUE046894T2 (hu) 2014-09-04 2020-04-28 Helsinn Healthcare Sa Anamorelinen alapuló gyógyászati kezelések
CN107001323A (zh) * 2015-10-20 2017-08-01 江苏恒瑞医药股份有限公司 一种阿拉莫林的结晶形式及其制备方法
US9837965B1 (en) 2016-09-16 2017-12-05 Peregrine Semiconductor Corporation Standby voltage condition for fast RF amplifier bias recovery
US20220323430A1 (en) 2019-08-30 2022-10-13 Helsinn Healthcare Sa Methods of manufacturing anamorelin tablets having improved stability

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960705808A (ko) * 1993-11-09 1996-11-08 조셉 에프. 디프리마 성장 호르몬의 방출을 촉진시키는 피페리딘, 피롤리딘 및 헥사하이드로-1H-아제핀(Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone)
JP4425992B2 (ja) * 1996-07-22 2010-03-03 サファイア セラピューティクス，インコーポレイティド 成長ホルモン放出特性を有する化合物
WO1999036431A1 (en) * 1998-01-16 1999-07-22 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6303620B1 (en) * 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
CA2329881C (en) * 1998-05-11 2010-03-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
JP2007531769A (ja) * 2004-03-30 2007-11-08 サファイア セラピューティクス インコーポレイテッド 成長ホルモン分泌促進薬を使用したｃ−反応性蛋白質の低減方法
CN1976921B (zh) 2004-06-29 2013-08-21 蓝宝石治疗公司 (3r)-1-(2-甲基丙氨酰-d-色氨酰)-3-(苯甲基)-3-哌啶羧酸1,2,2-三甲基酰肼的晶形

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012188452A (ja) * 2004-06-29 2012-10-04 Helsinn Therapeutics (Us) Inc （３ｒ）−１−（２−メチルアラニル−ｄ−トリプトフィル）−３−（フェニルメチル）−３−ピペリジンカルボン酸１，２，２−トリメチルヒドラジドの結晶形

Also Published As

Publication number Publication date
JP2008505078A (ja) 2008-02-21
CN102584937A (zh) 2012-07-18
US7825138B2 (en) 2010-11-02
CA2572325A1 (en) 2006-02-16
US20110003996A1 (en) 2011-01-06
CN103772483A (zh) 2014-05-07
EP1768976B1 (en) 2017-04-26
EP2298760B1 (en) 2015-08-05
JP5718286B2 (ja) 2015-05-13
US8466173B2 (en) 2013-06-18
IL180336A0 (en) 2007-07-04
EP2298760A1 (en) 2011-03-23
CN1976921B (zh) 2013-08-21
JP2012188452A (ja) 2012-10-04
EP1768976A1 (en) 2007-04-04
WO2006016995A1 (en) 2006-02-16
CA2572325C (en) 2013-08-27
CN102584937B (zh) 2017-03-01
CN1976921A (zh) 2007-06-06
HK1105000A1 (en) 2008-02-01
US20070004638A1 (en) 2007-01-04
KR20070030222A (ko) 2007-03-15
KR101324340B1 (ko) 2013-10-31
MXPA06015003A (es) 2007-08-07

Similar Documents

Publication Publication Date Title
JP5718286B2 (ja) （３ｒ）−１−（２−メチルアラニル−ｄ−トリプトフィル）−３−（フェニルメチル）−３−ピペリジンカルボン酸１，２，２−トリメチルヒドラジドの結晶形
US5767124A (en) Polymorphic forms of a growth hormone secretagogue
EP1060190A1 (en) New salt forms of (2e)- 5-amino-5- methylhex-2- enoic acid n-methyl-n-((1r)-1-(n- methyl-n-((1r)-1-(methylcarbamoyl)-2- phenylethyl)carbamoyl)-2- (2-naphtyl)ethyl)amide
TW201829423A (zh) Ｊａｎｕｓ激酶抑制劑之結晶型
US9975921B2 (en) Crystal forms of anamorelin
AU2005272074B2 (en) Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
HK1197827A (en) Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
HK1105000B (en) Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1, 2, 2-trimethylhydrazide
AU707946B2 (en) Polymorphic forms of a growth hormone secretagogue
US6281247B1 (en) Salt forms of (2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoyl)-2-(2-naphthyl)ethyl)amide
WO2017067438A1 (zh) 一种阿拉莫林的结晶形式及其制备方法
CZ20003152A3 (cs) Soli N-methyi-N-((lR)-l-(N-methyl-N-((lR)-l- (methylkarbamoyl)-2-fenylethyl)karbamoyl)-2 (2-naftyl)ethyl)amidu (2E)-5-amino-5-methylhex- 2-enové kyseliny
BRPI9611229B1 (pt) Polymorphic form of the compound of N- [1 (R) - [(1,2-dihydro-1-methanesulfonyl-spiro [3 H -indol-3,4'-piperdin] -1'-yl) carbonyl] -2- - (phenylmethyl oxy) ethyl] -2-amino-2-methylpropanamide and pharmaceutical composition
MXPA98003351A (en) ot. POLYMORPHIC FORMS OF A GROWTH HORMONE SECRETAGOGUE

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110615

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110915

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120614

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20120713

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120713

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120713

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120806

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120925

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121025

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151102

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5122950

Country of ref document: JP

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term